5 completed, 3 recruiting, 2 active not recruiting. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Recruiting 3, Active not recruiting 1 |
| Phase 2 | 6 | Active not recruiting 2, Completed 2, Recruiting 2 |
Follow Lethal Congenital Contracture Syndrome 2: new trials by email Literature Review of Lethal Congenital Contracture Syndrome 2 trials Research Report on Lethal Congenital Contracture Syndrome 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) BNT326, Pumitamig - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 880 | 2025-09-22 | 2026-10-22 |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors BNT326, Pumitamig, Itraconazole - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 1438 | 2025-08-12 | 2026-10-09 |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer BNT116, Cemiplimab, Docetaxel - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | BioNTech SE | 320 | 2022-06-17 | 2026-07-22 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. Zenocutuzumab, Trastuzumab, Vinorelbine - Breast Cancer Metastatic | Phase 2 | Completed | Merus B.V. | 105 | 2018-01-15 | 2024-03-07 |
| A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) zenocutuzumab (MCLA-128) - Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion | Phase 2 | Active not recruiting | Partner Therapeutics, Inc. | 250 | 2015-01-01 | 2025-04-29 |
| A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer MM-121, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Merrimack Pharmaceuticals | 162 | 2010-02-01 | 2016-08-22 |
| Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors U3-1287 (AMG888) - Advanced Solid Tumors | Phase 1 | Completed | U3 Pharma GmbH | 60 | 2008-08-01 | 2010-07-29 |
| Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment MM-121 - Advanced Solid Tumors | Phase 1 | Completed | Merrimack Pharmaceuticals | 44 | 2008-07-01 | 2016-09-01 |
| Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients Gene mutation analyses and FISH - Breast Cancer | Completed | Istituto Clinico Humanitas | 11 | 2007-10-01 | 2010-09-02 |
Carcinoma, Non-Small-Cell Lung (6) · Fibromatosis, Gingival, 2 (2) · Melanoma (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Multiple Endocrine Neoplasia Type 2a (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Bronchial Neoplasms (6) · Carcinoma, Bronchogenic (6) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Lung Neoplasms (5) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
seribantumab (2) · zenocutuzumab (2) · Anastrozole (1) · Antibodies, Bispecific (1) · Carboplatin (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Fulvestrant (1) · In Situ Hybridization, Fluorescence (1) · Itraconazole (1) · Letrozole (1) · Paclitaxel (1) · Paroxetine (1) · Trastuzumab (1) · Vascular Endothelial Growth Factor A (1)
BioNTech SE (3) · Merrimack Pharmaceuticals (2) · Cancer Research UK (1) · Istituto Clinico Humanitas (1) · Merus B.V. (1) · Partner Therapeutics, Inc. (1) · U3 Pharma GmbH (1)
United States (8) · Spain (6) · United Kingdom (6) · Germany (5) · Italy (4) · Australia (3) · Belgium (3) · Turkey (Türkiye) (3) · Canada (2) · China (2) · France (2) · Netherlands (2) · Poland (2) · South Korea (2) · Taiwan (2)
Alison Schram, MD (1) · Armando Santoro, MD (1) · Crystal Denlinger, MD (1) · Ernesto Wasserman, MD (1) · Johann de Bono, Prof (1) · Keedy L Vicki, MD (1) · Kwok Kin Wong, MD (1) · Victor Moyo, MD (1)
PMID 23591447, PMID 34250553, PMID 38348690, PMID 39908431
2014 (1), 2017 (1), 2023 (1)